Opioid Antagonist Nalmefene Shows Comparable Effectiveness to Naloxone
A Purdue Pharma study explored nalmefene and naloxone for the reversal of respiratory depression induced by fentanyl in a clinical opioid-induced respiratory depression model.
A Purdue Pharma study explored nalmefene and naloxone for the reversal of respiratory depression induced by fentanyl in a clinical opioid-induced respiratory depression model.
A Purdue Pharma study explored nalmefene and naloxone for the reversal of respiratory depression induced by fentanyl in a clinical opioid-induced respiratory depression model.
Read MoreThe CDC now recommends a second COVID-19 vaccine dose for people aged 65 and older, as well as those who are immunocompromised, six months after their initial dose.
Read MoreLowering the age gives more adults the opportunity to protect themselves from pneumococcal disease at an age when the risk of infection increases, according to the CDC.Â
Read MoreA surprising study found that Black patients were less likely to refuse vaccines compared to White patients.
Read MoreImplanted under the skin, the Naloximeter senses dropping oxygen and sends a warning notification to a mobile app. If the user doesn’t engage with the warning message within 30 seconds, the device releases stored naloxone.
Read MoreThe FDA has updated the label for Sanofi’s Flublok influenza vaccine to include safety data from a study of over 48,000 pregnant individuals.
Read MoreNew sub-analyses show that brensocatib reduced pulmonary exacerbations and slowed lung function decline for most subgroups of patients with non-cystic fibrosis bronchiectasis.
Read MoreThe FDA has approved Dupixent for adults with inadequately controlled COPD and an eosinophilic phenotype.
Read MoreAn NIH-funded analysis suggests higher doses of buprenorphine were associated with lower rates of emergency department visits or use of inpatient services related to behavioral health.
Read MoreResearchers investigated whether transparent capsules in dry powder inhalers improved medication delivery by providing visual feedback to patients.
Read MoreGilead has recalled one lot of Veklury (remdesivir) after confirming the presence of a glass particle in a vial following a customer complaint.
Read MoreA phase III study demonstrated that a single oral dose of Xofluza significantly reduced the spread of influenza within households.
Read MoreThe FDA has approved Dupixent as an add-on maintenance treatment for adolescents aged 12-17 with chronic rhinosinusitis with nasal polyps, expanding its original approval for adults in 2019.
Read MoreA survey found that 44% of Americans are likely to get a yearly COVID-19 vaccine if recommended by the CDC, a drop from 52% just eight months earlier.
Read MoreThe American College of Physicians is advising adults to get all recommended vaccines to protect against preventable diseases and reduce the spread of infection.
Read MoreThe vaccine candidate showed strong responses against influenza A and COVID-19 but did not meet its goal for influenza B.
Read MoreThe approval was based on trial results which showed the regimen reduced the risk of recurrence, progression, or death by 32% versus neoadjuvant chemotherapy alone.
Read MoreThe FDA approved Zurnai, a nalmefene hydrochloride auto-injector, for emergency opioid overdose treatment in individuals aged 12 and older.
Read MoreThe trial showed that clesrovimab reduced RSV-related respiratory infections in infants through day 150.
Read MoreThe unexpected finding of pre-existing T-cell reactivity to the AstraZeneca and Janssen vaccines may explain why some people rarely developed thrombotic thrombocytopenia syndrome after vaccination.
Read MoreThe study results confirm omadacycline as a safe and effective treatment for moderate to severe community-acquired bacterial pneumonia, demonstrating non-inferiority to moxifloxacin.
Read MoreAdding a newly identified compound makes naloxone more potent and longer lasting, a mouse study shows.
Read MoreThe CDC advises everyone 6 months and older to receive the updated 2024-2025 COVID-19 and flu vaccines to protect against severe respiratory illnesses this upcoming season.
Read MoreThe inhaled therapy for the maintenance treatment of COPD combines bronchodilator and non-steroidal anti-inflammatory activities in one molecule.
Read More